202 related articles for article (PubMed ID: 36737429)
21. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.
Shkreta L; Bell B; Revil T; Venables JP; Prinos P; Elela SA; Chabot B
Cancer Treat Res; 2013; 158():41-94. PubMed ID: 24222354
[TBL] [Abstract][Full Text] [Related]
22. Aberrant splicing events caused by insertion of genes of interest into expression vectors.
Cheng Y; Kang XZ; Chan P; Ye ZW; Chan CP; Jin DY
Int J Biol Sci; 2022; 18(13):4914-4931. PubMed ID: 35982889
[No Abstract] [Full Text] [Related]
23. Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells.
de Lange P; Segeren CM; Koper JW; Wiemer E; Sonneveld P; Brinkmann AO; White A; Brogan IJ; de Jong FH; Lamberts SW
Cancer Res; 2001 May; 61(10):3937-41. PubMed ID: 11358809
[TBL] [Abstract][Full Text] [Related]
24. Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks.
Sebestyén E; Singh B; Miñana B; Pagès A; Mateo F; Pujana MA; Valcárcel J; Eyras E
Genome Res; 2016 Jun; 26(6):732-44. PubMed ID: 27197215
[TBL] [Abstract][Full Text] [Related]
25. RNA splicing factors in normal hematopoiesis and hematologic malignancies: novel therapeutic targets and strategies.
Li Z; He Z; Wang J; Kong G
J Leukoc Biol; 2023 Feb; 113(2):149-163. PubMed ID: 36822179
[TBL] [Abstract][Full Text] [Related]
26. [Pre-mRNA splicing: when the spliceosome loses ground].
Dujardin G; Daguenet É; Bernard DG; Flodrops M; Durand S; Chauveau A; El Khoury F; Le Jossic-Corcos C; Corcos L
Med Sci (Paris); 2016 Dec; 32(12):1103-1110. PubMed ID: 28044974
[TBL] [Abstract][Full Text] [Related]
27. Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics.
Bessa C; Matos P; Jordan P; Gonçalves V
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261131
[TBL] [Abstract][Full Text] [Related]
28. Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets.
Adamia S; Pilarski PM; Belch AR; Pilarski LM
Curr Cancer Drug Targets; 2013 May; 13(4):347-61. PubMed ID: 23517594
[TBL] [Abstract][Full Text] [Related]
29. Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.
Jyotsana N; Heuser M
Expert Opin Ther Targets; 2018 Feb; 22(2):107-121. PubMed ID: 29235382
[TBL] [Abstract][Full Text] [Related]
30. Rules and tools to predict the splicing effects of exonic and intronic mutations.
Ohno K; Takeda JI; Masuda A
Wiley Interdiscip Rev RNA; 2018 Jan; 9(1):. PubMed ID: 28949076
[TBL] [Abstract][Full Text] [Related]
31. Aberrant splicing in human cancer: An RNA structural code point of view.
Apostolidi M; Stamatopoulou V
Front Pharmacol; 2023; 14():1137154. PubMed ID: 36909167
[TBL] [Abstract][Full Text] [Related]
32. Aberrant RNA splicing and therapeutic opportunities in cancers.
Yamauchi H; Nishimura K; Yoshimi A
Cancer Sci; 2022 Feb; 113(2):373-381. PubMed ID: 34812550
[TBL] [Abstract][Full Text] [Related]
33. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
34. Aberrant RNA splicing of the protein C and protein S genes in healthy individuals.
Berg LP; Soria JM; Formstone CJ; Morell M; Kakkar VV; Estivill X; Sala N; Cooper DN
Blood Coagul Fibrinolysis; 1996 Sep; 7(6):625-31. PubMed ID: 8899152
[TBL] [Abstract][Full Text] [Related]
35. HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395.
Sun G; Zhou H; Chen K; Zeng J; Zhang Y; Yan L; Yao W; Hu J; Wang T; Xing J; Xiao K; Wu L; Ye Z; Xu H
J Exp Clin Cancer Res; 2020 Jun; 39(1):116. PubMed ID: 32560659
[TBL] [Abstract][Full Text] [Related]
36. Genome wide identification of aberrant alternative splicing events in myotonic dystrophy type 2.
Perfetti A; Greco S; Fasanaro P; Bugiardini E; Cardani R; Garcia-Manteiga JM; Riba M; Cittaro D; Stupka E; Meola G; Martelli F
PLoS One; 2014; 9(4):e93983. PubMed ID: 24722564
[TBL] [Abstract][Full Text] [Related]
37. Splicing factor mutations in hematologic malignancies.
Chen S; Benbarche S; Abdel-Wahab O
Blood; 2021 Aug; 138(8):599-612. PubMed ID: 34157091
[TBL] [Abstract][Full Text] [Related]
38. Identifying genes with conserved splicing structure and orthologous isoforms in human, mouse and dog.
Guillaudeux N; Belleannée C; Blanquart S
BMC Genomics; 2022 Mar; 23(1):216. PubMed ID: 35303798
[TBL] [Abstract][Full Text] [Related]
39. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array.
Gardina PJ; Clark TA; Shimada B; Staples MK; Yang Q; Veitch J; Schweitzer A; Awad T; Sugnet C; Dee S; Davies C; Williams A; Turpaz Y
BMC Genomics; 2006 Dec; 7():325. PubMed ID: 17192196
[TBL] [Abstract][Full Text] [Related]
40. Aberrant alternative splicing of human zinc finger gene ZNF268 in human hematological malignancy.
Zhao Z; Wang D; Zhu C; Shao H; Sun C; Qiu H; Xue L; Xu J; Guo M; Li W
Oncol Rep; 2008 Nov; 20(5):1243-8. PubMed ID: 18949428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
